These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease]. Dzudza M; Dzudza D Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968 [No Abstract] [Full Text] [Related]
16. [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease]. Gründig E; Gerstenbrand F; Oberhummer J; Simanyi M; Schedl R; Weiss J Z Neurol; 1972; 203(1):73-90. PubMed ID: 4118094 [No Abstract] [Full Text] [Related]
17. [L-Dopa therapy in Parkinson's disease. A double-blind study]. Worm-Petersen J; Dupont E; Mikkelsen B Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651 [No Abstract] [Full Text] [Related]
18. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor]. Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743 [No Abstract] [Full Text] [Related]
19. Age bias in clinical trials of Parkinson's disease treatment. Rajapakse A; Rajapakse S; Playfer J J Am Geriatr Soc; 2008 Dec; 56(12):2353-4. PubMed ID: 19093937 [No Abstract] [Full Text] [Related]
20. Continuing trials of GDNF in Parkinson's disease. Barker RA Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740 [No Abstract] [Full Text] [Related] [Next] [New Search]